Mostrando 2 resultados de: 2
3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer
ArticleAbstract: Prostate cancer usually responds to androgen deprivation therapy, although the response in metastatiPalabras claves:Autores:Evaul K., Li R., Papari-Zareei M., Richard J. Auchus, Sharifi N.Fuentes:scopusAbiraterone inhibits 3β-hydroxysteroid dehydrogenase: A rationale for increasing drug exposure in castration-resistant prostate cancer
ArticleAbstract: Purpose: Treatment with abiraterone (abi) acetate prolongs survival in castration-resistant prostatePalabras claves:Autores:Chang K.H., Evaul K., Li R., Liu J., Richard J. Auchus, Sharifi N., Sharma K.K., Yoshimoto J.A.Fuentes:scopus